PURPOSE: Numerous studies have reported excellent local control using SBRT for treatment of early stage non-small cell lung cancer. We report our single institution experience in using protracted course of SBRT (compared to standard 3-5 fractions used for curative intent) as a palliative treatment for lung tumors.
METHODS: Patients with symptomatic lung lesions treated with palliative intent SBRT were retrospectively reviewed. These patients were not amenable to curative treatment due to previous irradiation, large sized lesions, or advanced disease. Patients received 50-52 Gy in 10-12 fractions daily for 2 weeks.
RESULTS: Ten patients, 5 males and 5 females, were treated over a three-year period. Seven primary, 2 metastatic, and 1 recurrent primary lesions were treated. Ages ranged from 41-84 with a mean age of 72 years. With a median follow-up of 11.5 months, the median overall survival was 18 months. Of 14 symptoms that were treated, 9 (64%) had complete resolution. Two symptoms treated (14%) partially improved and two symptoms (14%) did not respond. One symptom (7%) worsened following treatment. The median time to response was 27 days. Symptoms relapsed in three patients with median time of 3.7 months. A majority of patients (70%) remained symptom free until last follow-up. None of the patients experienced grade 3 or higher toxicity.
CONCLUSIONS: SBRT is a safe, effective, and durable treatment modality for palliating lung tumors that are not suitable for curative treatment.
CLINICAL IMPLICATIONS: Patients with symptomatic lung lesions that are not seeking or may not benefit from curative treatment can be treated safely with SBRT and receive durable symptomatic relief.
DISCLOSURE: The following authors have nothing to disclose: Beant Gill, Ajay Sandhu, Daniel Kim, Lyudmila Bazhenova, Polly Nobiensky, William Read
No Product/Research Disclosure Information